Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for medical industry professionals · Sunday, September 23, 2018 · 462,760,542 Articles · 3+ Million Readers

Advanced Bifurcation Systems Announces Plans for Asian Expansion

Heart Disease is a pandemic in Asia. Today Los Angeles based Advanced Bifurcation Systems executives announce the company's Asian strategy.

LOS ANGELES, CALIFORNIA, UNITED STATES, March 12, 2018 / -- Advanced Bifurcation Systems (ABS), a medical stenting technology company, today announced plans to increase their footprint in Asian markets. The company has been developing a revolutionary stenting technology that has the potential to simplify such procedures and reduce the financial burden on healthcare systems.

The announcement of their Asian expansion plans coincides with an ambitious new investment fundraising campaign. CEO Charles Laverty has set a goal of raising an additional $20 million in funds, which will be used to further develop their stenting technology through clinical trials. Initial trial results have been overwhelmingly successful and ABS is on track to obtain regulatory approval within the next couple of years.

The company’s Chief Medical Officer, Dr. Mehran Khorsandi, believes that Asian healthcare systems are natural partners for ABS due to their steadily increasing rates of heart disease. In China for example, heart disease affects 1 out of every 5 adults. There’s a clear need for new and innovative medical solutions such as the one being developed by ABS.

Their system is a new stenting procedure that’s designed to successfully treat bifurcation lesions in cardiac patients. A dual catheter is used to place stents in both the mother and daughter arteries at the same time. The system reduces the amount of errors and simplifies the procedure. Trials so far have been highly successful.

The Asian market represents a great opportunity for ABS and Laverty considers it essential to the company’s success. Almost 60% of the world’s population lives in the region and those numbers are projected to rise in the coming decades. It’s a major market and the company believes their technology can help it to reduce the growing number of deaths due to heart disease.

CEO Laverty has plans to visit Asia several more times in the next year in a bid to strengthen its relationship with its new Asian partners. It’s also working to develop new ones. It’s all part of a coherent global growth strategy.
Advanced Bifurcation Systems is an innovator in the medical device industry. Its medical stenting technology could potentially alter the landscape significantly in the treatment of coronary angioplasties. Their seamless method for stenting branched arteries is a unique approach that has the backing of many medical experts. More information about the company and their new technology can be found on their website at

Charles Laverty
Advanced Bifurcation Systems
email us here

Powered by EIN Presswire